BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...and LF Investment in the round.Vivace picks up the pace with series CBoxer Capital led Vivace Therapeutics Inc.’s...
...2D membrane retina-specificROR2 - Receptor tyrosine kinase-like orphan receptor 2YAP1 (YAP) - Yes-associated protein 1 Paul Bonanos Vivace Therapeutics Inc. MinervaX...
BioCentury | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

...a Regeneron Pharmaceutical Inc. board member since 1988; and SAB member Leonard Post, CSO at Vivace Therapeutics Inc....
...Inc. (NASDAQ:RTRX), San Diego, Calif. Sangamo Therapeutics Inc. (NASDAQ:SGMO), Richmond, Calif. Stanford University, Stanford, Calif. Vivace Therapeutics Inc....
BioCentury | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

...challenge has been that there’s no molecule target,” said Sofie Qiao, President and CEO of Vivace Therapeutics Inc....
...I think most of the challenge has been that there’s no molecule target.” Sofie Qiao, Vivace Therapeutics...
...sort out the function of each TEAD over the next couple of years.” Leonard Post, Vivace Therapeutics...
BioCentury | Nov 16, 2017
Emerging Company Profile

YAP off, YAP on

...has filed an undisclosed number of patent applications covering modulation of Hippo-YAP signaling. COMPANY PROFILE Vivace Therapeutics Inc....
...Darmstadt, Germany Reliance Life Sciences, Rabale, India University of California San Diego, La Jolla, Calif. Vivace Therapeutics Inc....
...“The Hippo pathway kinases LATS1/2 suppress cancer immunity.” Cell (2016) Michael Leviten, Senior Writer Cancer Research UK Merck KGaA UCSF Vivace Therapeutics Inc. Large...
BioCentury | Sep 14, 2017
Targets & Mechanisms

Platelets YAP at cancer

...that are addicted to the pathway being turned on based on genetic mutations.” Leonard Post, Vivace Therapeutics...
...said Sood. According to BioCentury, no companies have disclosed compounds targeting YAP1 directly. In June, Vivace Therapeutics Inc....
...Institutes of Health (NIH), Bethesda, Md. University of Texas MD Anderson Cancer Center, Houston, Texas Vivace Therapeutics Inc....
BioCentury | Aug 3, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

...1 (LATS1) Vivace Therapeutics Inc. is developing small molecule inhibitors of LATS1 and LATS2 to treat cancer. Vivace Therapeutics Inc....
BioCentury | Jul 5, 2017
Finance

Cross-border cachet

...programs are based on IP developed by Chinese nationals working at U.S. universities. Stephen Hansen, Associate Editor Vivace Therapeutics Inc....
BioCentury | Jul 5, 2017
Financial News

Vivace emerges from stealth with $25M series B round

...$410 million up front (see BioCentury, Sept. 21, 2015 ). Vivace Therapeutics Inc. , San Mateo, Calif. Alex Himes Vivace Therapeutics Inc....
BioCentury | Jun 28, 2017
Financial News

Vivace out of stealth with $40M in two rounds

...Cancer play Vivace Therapeutics Inc. (San Mateo, Calif.) emerged from stealth mode and announced a $25 million series...
BioCentury | Jan 26, 2015
Financial News

Vivace Therapeutics completes venture financing

Vivace Therapeutics Inc. , Orinda, Calif. Business: Cancer Date completed: 2015-01-20 Type: Venture financing Raised: $5.1 million Investor: Not disclosed Note: The company raised $5.1 million, according to an SEC filing. WIR Staff cancer...
Items per page:
1 - 10 of 10
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...and LF Investment in the round.Vivace picks up the pace with series CBoxer Capital led Vivace Therapeutics Inc.’s...
...2D membrane retina-specificROR2 - Receptor tyrosine kinase-like orphan receptor 2YAP1 (YAP) - Yes-associated protein 1 Paul Bonanos Vivace Therapeutics Inc. MinervaX...
BioCentury | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

...a Regeneron Pharmaceutical Inc. board member since 1988; and SAB member Leonard Post, CSO at Vivace Therapeutics Inc....
...Inc. (NASDAQ:RTRX), San Diego, Calif. Sangamo Therapeutics Inc. (NASDAQ:SGMO), Richmond, Calif. Stanford University, Stanford, Calif. Vivace Therapeutics Inc....
BioCentury | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

...challenge has been that there’s no molecule target,” said Sofie Qiao, President and CEO of Vivace Therapeutics Inc....
...I think most of the challenge has been that there’s no molecule target.” Sofie Qiao, Vivace Therapeutics...
...sort out the function of each TEAD over the next couple of years.” Leonard Post, Vivace Therapeutics...
BioCentury | Nov 16, 2017
Emerging Company Profile

YAP off, YAP on

...has filed an undisclosed number of patent applications covering modulation of Hippo-YAP signaling. COMPANY PROFILE Vivace Therapeutics Inc....
...Darmstadt, Germany Reliance Life Sciences, Rabale, India University of California San Diego, La Jolla, Calif. Vivace Therapeutics Inc....
...“The Hippo pathway kinases LATS1/2 suppress cancer immunity.” Cell (2016) Michael Leviten, Senior Writer Cancer Research UK Merck KGaA UCSF Vivace Therapeutics Inc. Large...
BioCentury | Sep 14, 2017
Targets & Mechanisms

Platelets YAP at cancer

...that are addicted to the pathway being turned on based on genetic mutations.” Leonard Post, Vivace Therapeutics...
...said Sood. According to BioCentury, no companies have disclosed compounds targeting YAP1 directly. In June, Vivace Therapeutics Inc....
...Institutes of Health (NIH), Bethesda, Md. University of Texas MD Anderson Cancer Center, Houston, Texas Vivace Therapeutics Inc....
BioCentury | Aug 3, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

...1 (LATS1) Vivace Therapeutics Inc. is developing small molecule inhibitors of LATS1 and LATS2 to treat cancer. Vivace Therapeutics Inc....
BioCentury | Jul 5, 2017
Finance

Cross-border cachet

...programs are based on IP developed by Chinese nationals working at U.S. universities. Stephen Hansen, Associate Editor Vivace Therapeutics Inc....
BioCentury | Jul 5, 2017
Financial News

Vivace emerges from stealth with $25M series B round

...$410 million up front (see BioCentury, Sept. 21, 2015 ). Vivace Therapeutics Inc. , San Mateo, Calif. Alex Himes Vivace Therapeutics Inc....
BioCentury | Jun 28, 2017
Financial News

Vivace out of stealth with $40M in two rounds

...Cancer play Vivace Therapeutics Inc. (San Mateo, Calif.) emerged from stealth mode and announced a $25 million series...
BioCentury | Jan 26, 2015
Financial News

Vivace Therapeutics completes venture financing

Vivace Therapeutics Inc. , Orinda, Calif. Business: Cancer Date completed: 2015-01-20 Type: Venture financing Raised: $5.1 million Investor: Not disclosed Note: The company raised $5.1 million, according to an SEC filing. WIR Staff cancer...
Items per page:
1 - 10 of 10